- NCIt
- C4503
Loading cancer entity…
Loading cancer entity…
Clinical trials
17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06488378 | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 |
| NCT07307664 | Increasing Germline Genetic Testing for Patients With Cancer(gLHS) | recruiting | N/A | 1,000 | Josh PetersonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04169542 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | recruiting | — | 600 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04125914 | Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families | active not recruiting | N/A | 384 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02595905 | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | completed | Phase 2 | 344 | National Cancer Institute (NCI)NIH | 2 | Apr 8, 2026 | clinicaltrials |
| NCT07292246 | A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)(ATHENA I) | recruiting | N/A | 15 | Vasileios KallesOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT01230346 | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | active not recruiting | N/A | 493 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | recruiting | Phase 2 | 23 | Okayama UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06516289 | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | recruiting | Phase 2 | 130 | Fudan UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04197856 | Direct Information to At-risk Relatives(DIRECT) | unknown | N/A | 490 | Umeå UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05763472 | Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation(Gen-eva) | unknown | — | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT03959267 | Testing a Culturally Adapted Telephone Genetic Counseling Intervention | completed | N/A | 37 | Georgetown UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT02557776 | Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer(BRCAsearch) | completed | N/A | 542 | Lund UniversityOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT03495544 | Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer | unknown | — | 390 | Tatarstan Cancer CenterOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 71 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials